<DOC>
	<DOCNO>NCT01550458</DOCNO>
	<brief_summary>The objective study determine safety pharmacokinetics 7 day course oral mibefradil give four time day healthy volunteer . This dose escalation study total daily dose mibefradil increase cohort .</brief_summary>
	<brief_title>Safety Study Mibefradil When Given Four Times Day Healthy Volunteers</brief_title>
	<detailed_description>This study establish safety , detailed pharmacokinetics , , possibly , maximum tolerate dose ( MTD ) ascend dos mibefradil administer four time day ( QID ) healthy volunteer . The knowledge gain guide detail study Interlaced Therapy™ patient recurrent High Grade Glioma ( HGG ) . Non-clinical study currently on-going efficacy Interlaced Therapy™ ovarian cancer , pancreatic cancer , intracranial malignancy .</detailed_description>
	<mesh_term>Mibefradil</mesh_term>
	<criteria>1 . Normal healthy volunteer age 19 55 year , male female , willing able sign inform consent ; 2 . Females must negative pregnancy test screen practice suitable method birth control , opinion Investigator , become pregnant course study , female postmenopausal ( menstrual period one year ) surgically sterilize . Females must either sexually inactive ( abstinent ) 14 day prior Screening remain 30 day follow final dosing study drug use one follow acceptable method birth control time specify : Barrier method ( condom diaphragm ) spermicidal least 14 day prior Screening Day 1 30 day follow final dosing study drug ; Surgical sterilization ( vasectomy ) partner least 6 month prior Day 1 ; Females nonchildbearing potential undergone one follow sterilization procedure least 6 month prior Day 1 : bilateral tubal ligation , hysterectomy , hysterectomy unilateral bilateral oophorectomy , bilateral oophorectomy . 3 . Male subject must continue use approve contraceptive method 60 day participate study . 4 . Has body mass index ( BMI ) 18.0 32.0 kg/m² , inclusive ; 5 . Have acute illness chronic health issue require medication . 1 . History investigational drug use within 30 day study ; 2 . Subject clinically significant disorder , opinion Investigator , could result subject 's inability understand comply requirement study ; 3 . History hypertension , treat untreated , screen BP &gt; 140 mm Hg systolic &gt; 90 mm Hg diastolic ; 4 . Currently within last 14 day take medication ( prescription , nonprescription , herbal Chinese remedy ) include oral contraceptive hormone replacement therapy ; 5 . Subject history impair hepatic function , Investigator 's opinion , contraindicate participation study ; subject abnormal laboratory value clinical significance study Investigators opinion ; 6 . Current smoker ( 10 cigarettes/day ) 6 month ; 7 . Subject creatinine clearance ( CLcr ) less 70 mL/min calculate CockroftGault equation : CLcr = ( ( 140 age ) x body mass x [ 0.85 female ] ) / ( 72 x creatinine ) age give year , body mass give kg , creatinine give mg/dL ; 8 . Subject history , sign , symptom ischemic cardiac , cerebrovascular , peripheral vascular syndrome significant underlying cardiovascular disease clinically significant Investigator 's opinion . This include known cardiac rhythm disorder ECG abnormality ; 9 . Subject , Investigator 's opinion , likely unrecognized cardiovascular disease , base history presence risk factor ; 10 . Subject currently take take previous 14 day , herbal preparation contain St. John 's Wort ( Hypericum perforatum ) ; 11 . Subject history allergic reaction calcium channel antagonist ; 12 . Females pregnant , actively try become pregnant , lactate . Females must practice suitable method birth control ( adequate barrier method birth control ; abstinence ) , opinion Investigator , become pregnant course study , female postmenopausal ( menstrual period one year ) surgically sterilize ; 13 . Subject recent history ( past 3 month ) suggestive evidence alcohol drug abuse dependence , unaccountedfor drug alcohol original drug screen ( test positive ) ; 14 . Allergy latex rubber ; 15 . Hemoglobin laboratory lower limit normal ; 16 . Significant blood loss 500 mL great blood donation within 56 day prior Day 1 . Subjects donate plasma within 5 day prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Clinical Trial , Phase I</keyword>
	<keyword>Human Volunteers</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>mibefradil</keyword>
	<keyword>Posicor®</keyword>
</DOC>